Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction
Results of this cohort study reveal that peri-CVE anti-VEGF was not associated with increased mortality or morbidity. Outcomes did not differ among commonly used agents, supporting the safety of continuing intravitreal anti-VEGF therapy without modification during the peri-CVE period.
Authors
- Darius Bordbar (ORCID: https://orcid.org/0000-0002-0649-9901)
- Amer F. Alsoudi (ORCID: https://orcid.org/0000-0002-2492-1993)
- Ali Mukhtar
- Asad Loya
- Ahmed B. Sallam
- Christina Y. Weng
- Jawad Muayad
- Nimesh A. Patel
- Muhammad Z. Chauhan
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Boston Children's Hospital (US)
- Harvard University (US)
- Baylor College of Medicine (US)
- Methodist Hospital (US)
- Associated Retinal Consultants (US)
- University of Arkansas for Medical Sciences (US)
- Texas A&M University (US)
- Bryan College (US)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1001/jamaophthalmol.2026.0460
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00